Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Defining critical roles for NF-κB p65 and type I interferon in innate immunity to rhinovirus.

Nathan W Bartlett | Louise Slater | Nicholas Glanville | Jennifer J Haas | Gaetano Caramori | Paolo Casolari | Deborah L Clarke | Simon D Message | Julia Aniscenko | Tatiana Kebadze | Jie Zhu | Patrick Mallia | Joseph P Mizgerd | Maria Belvisi | Alberto Papi | Sergei V Kotenko | Sebastian L Johnston | Michael R Edwards
EMBO molecular medicine | 2012

The importance of NF-κB activation and deficient anti-viral interferon induction in the pathogenesis of rhinovirus-induced asthma exacerbations is poorly understood. We provide the first in vivo evidence in man and mouse that rhinovirus infection enhanced bronchial epithelial cell NF-κB p65 nuclear expression, NF-κB p65 DNA binding in lung tissue and NF-κB-regulated airway inflammation. In vitro inhibition of NF-κB reduced rhinovirus-induced pro-inflammatory cytokines but did not affect type I/III interferon induction. Rhinovirus-infected p65-deficient mice exhibited reduced neutrophilic inflammation, yet interferon induction, antiviral responses and virus loads were unaffected, indicating that NF-κB p65 is required for pro-inflammatory responses, but redundant in interferon induction by rhinoviruses in vivo. Conversely, IFNAR1(-/-) mice exhibited enhanced neutrophilic inflammation with impaired antiviral immunity and increased rhinovirus replication, demonstrating that interferon signalling was critical to antiviral immunity. We thus provide new mechanistic insights into rhinovirus infection and demonstrate the therapeutic potential of targeting NF-κB p65 (to suppress inflammation but preserve anti-viral immunity) and type I IFN signalling (to enhance deficient anti-viral immunity) to treat rhinovirus-induced exacerbations of airway diseases.

Pubmed ID: 23165884

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: Medical Research Council, United Kingdom
    Id: G1000758
  • Agency: Medical Research Council, United Kingdom
    Id: G1100168
  • Agency: Medical Research Council, United Kingdom
    Id: G0601236
  • Agency: PHS HHS, United States
    Id: P26095
  • Agency: Medical Research Council, United Kingdom
    Id: G0800195
  • Agency: Wellcome Trust, United Kingdom
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL079392

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Clontech (tool)

RRID:SCR_004423

An Antibody supplier

View all literature mentions

BioVision (tool)

RRID:SCR_005057

An Antibody supplier

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions

BEAS-2B (tool)

RRID:CVCL_0168

Cell line BEAS-2B is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions

BALB/cAnNCrl (tool)

RRID:MGI:2683685

laboratory mouse with name BALB/cAnNCrl from MGI.

View all literature mentions

HeLa (tool)

RRID:CVCL_0030

Cell line HeLa is a Cancer cell line with a species of origin Homo sapiens

View all literature mentions